Evidence map›Paper›PMID 41234148›Full record

ArticleACS applied materials & interfaces2025

Effects of Serum Incubation on Lipid Nanoparticle PEG Shedding, mRNA Retention, and Membrane Interactions.

Simon Niederkofler, Petteri Parkkila, Nima Aliakbarinodehi, Nima Sasanian, Gustav Emilsson, David Ulkoski, Celso J O Ferreira, Nicole Stéphanie Galenkamp, Bruno F B Silva, Dan Lundberg and 4 more

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Simon NiederkoflerDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Fysikgränd 3, Göteborg 41296, Sweden.ORCID 0009-0006-6893-1444
Petteri ParkkilaDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Fysikgränd 3, Göteborg 41296, Sweden.ORCID 0000-0002-2717-0232
Nima AliakbarinodehiDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Fysikgränd 3, Göteborg 41296, Sweden.ORCID 0000-0002-8814-4695
Nima SasanianDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Fysikgränd 3, Göteborg 41296, Sweden.ORCID 0009-0006-0328-7555
Gustav EmilssonAdvanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg 431 83, Sweden.ORCID 0000-0002-5030-3953
David UlkoskiAdvanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca Boston, Waltham, Massachusetts 02451, United States.ORCID 0000-0001-5284-1977
Celso J O FerreiraINL-International Iberian Nanotechnology Laboratory, Braga 4715-330, Portugal.ORCID 0000-0001-8577-3755
Nicole Stéphanie GalenkampDepartment of Chemistry, Physical Chemistry, Lund University, Naturvetarvägen 14, Lund 22100, Sweden.ORCID 0000-0002-6462-0159
Bruno F B SilvaINL-International Iberian Nanotechnology Laboratory, Braga 4715-330, Portugal.ORCID 0000-0002-8997-6311
Dan LundbergAdvanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg 431 83, Sweden.ORCID 0000-0001-9392-9537
Yujia JingAdvanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg 431 83, Sweden.ORCID 0000-0002-6060-5197
Lennart LindforsAdvanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg 431 83, Sweden.ORCID 0000-0002-6711-0605
Björn AgnarssonDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Fysikgränd 3, Göteborg 41296, Sweden.ORCID 0000-0003-3364-7196
Fredrik HöökDepartment of Physics, Division of Nano and Biophysics, Chalmers University of Technology, Fysikgränd 3, Göteborg 41296, Sweden.ORCID 0000-0003-1994-5015

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) are widely used for RNA delivery, but their efficiency remains limited, largely due to poor endosomal escape. Upon administration, proteins bind to the surface of the LNPs, influencing cellular uptake and potentially altering their interfacial properties. Such alterations may also affect their interaction with endosomal membranes, thus influencing the critical endosomal escape step. Using fluorescence microscopy imaging with single-LNP resolution, this study investigates how incubation in 10% fetal bovine serum alters the PEG modification and mRNA content of LNPs, as well as how serum incubation-induced alterations influence the interaction between LNPs and an anionic supported lipid bilayer (SLB), serving as a simplistic mimic for the anionic lipid membrane of late endosomes. We demonstrate that serum incubation leads to the desorption of PEG-modified lipids and a significant release of mRNA cargo from the LNPs. PEG shedding occurred consistently with a half-life time of around 10 min, while mRNA release displayed higher variability between individual LNPs. We also observed that serum preincubation enhanced attractive interactions between tethered LNPs and the anionic SLB at physiological pH 7.4, and fusion of LNPs with the anionic SLB upon pH reduction was more efficient for serum-preincubated LNPs than for their pristine counterparts, particularly during moderate acidification from pH 6.5 to 6.0. This enhanced fusion efficiency may be attributed to a reduced steric hindrance from PEG-lipids following serum preincubation. The findings highlight that serum-induced modifications enhance LNP fusion efficiency with an endosomal membrane mimic while potentially compromising mRNA retention, thus balancing the overall efficacy of LNP-assisted mRNA delivery.

Indexed as

LipidsNanoparticlesPolyethylene GlycolsRNA, MessengerSerumAnimalsCattleEndosomesHumansLipid BilayersLiposomesLipid BilayersLipid NanoparticlesLipidsLiposomesPolyethylene GlycolsRNA, Messengerendosomal escapeendosomal membrane mimiclipid nanoparticle (LNP)mRNA deliveryPEG sheddingprotein corona

Identifiers

PMID41234148
PMCPMC12673520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.